Oncology (Medical)

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study To Compare Standard Therapy To Treat Hodgkin Lymphoma To The Use Of Two Drugs, Brentuximab Vedotin And Nivolumab

   Rochester, Minn., Jacksonville, Fla.

   The purpose of this study is to compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage cHL who have a rapid early response (RER) as determined by PET2 after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy. Also, to compare the PFS of a standard chemotherapy approach versus an IO therapy approach (brentuximab vedotin and nivolumab) plus involved site radiation therapy (ISRT) in patients with newly diagnosed early stage cHL who have a slow early response (SER) as determined by PET2 after 2 cycles of ABVD chemotherapy.

2. Image-based Mapping Of Brain Tumors

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment.

    

3. A Study To Evaluate Oncologic Outcomes And Quality Of Life In Sinonasal Cancer Patients

   Rochester, Minn.

   This is a multi-site study with several other leading centers studying sinonasal cancers. The purpose of this study is to gain a better understanding of the treatment and significant morbidity associated with sinonasal cancer and identify the impact this disease has on quality of life. In addition, several additional endpoints will focus on survival and optimal treatment strategies. Additional components will also included genomic and molecular analysis of tumor tissue as we search for novel targets for therapy.

    

    

4. Long-Term Follow-up Protocol For Participants Treated With Gene-Modified T Cells

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.
   
   Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

5. Tumor Treating Fields For The Treatment Of Leptomeningeal Metastases Of The Spine In Patients With Breast Or Lung Cancer

   Jacksonville, Fla.

   This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with breast or lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Patients wear the portable Novo TTF-200T device that produces electric fields to target areas on the body to stop the growth of tumor cells. The information from this study will help researchers develop a better treatment for leptomeningeal metastases in the future.

6. Testicular Tissue Cryopreservation In Children

   Rochester, Minn.

   This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential.

7. Global Trial In APG2575 For Patients With CLL/​SLL

   Jacksonville, Fla.

   The purpose of this study is to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

8. 3D Ultrasound Imaging For Breast Cancer Diagnosis

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveess of a new 3D ultrasound imaging technology combining B-mode, microvessel imaging, shear wave elastography, and machine learning for breast lesion diagnosis.

9. Phase 1 Trial Of ST-001 NanoFenretinide In Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

   Scottsdale/Phoenix, Ariz.

   This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).

10. Actinium Therapy For Late-stage Aggressive Sarcomas

    Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

    The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.

    The main questions the study aims to answer in Phase/Part 1 of the trial are:

    • Is [Ac225]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.

    • What is the most tolerable dose of [Ac225]RTX-2358

    • Does the treatment show effectiveness on advanced sarcoma

    Participants will:

    • Take drug [Ac225]RTX-2358 once every 8 weeks (4 cycle target; 6 cycle maximum) over a period of 12 months

    • Visit the clinic three times for the first week of cycle one, then once a week for the remaining 7 weeks of cycle 1 for check-ups and tests.

    • For cycles 2-6: patient will visit the clinic once every 2 weeks for checkups and tests

    • Remain in long term follow-up for a period of four additional years